title: Double-delayed intensification paediatric protocol without radiotherapy is an efficient treatment in adult lymphoblastic lymphoma.
abstract: Lymphoblastic lymphoma (LBL) is a rare disease associated with favourable prognosis in childhood but with poor prognosis in adults when treated with conventional non-Hodgkin lymphoma regimens. Improvements in long-term outcome have been made since the use of acute lymphoblastic leukaemia (ALL) regimens. We report here the feasibility of a double-delayed intensification paediatric protocol in 12 adult LBL patients. There were no relapses and no deaths, with a median follow-up of 4.7 years. Using the same protocol, overall survival was significantly longer in LBL patients versus ALL patients (100% vs 75%, p = 0.05). Overall tolerance was acceptable and better in ALL patients. We have shown the feasibility and the good results of using this paediatric protocol in LBL.
authors.affiliation: Département d'Hématologie, Hôpital Saint-Antoine, APHP and Université Pierre et Marie Curie, Paris, France.
authors.forename: Elise
authors.initials: E
authors.lastname: Corre
authors.forename: Zora
authors.initials: Z
authors.lastname: Marjanovic
authors.forename: Simona
authors.initials: S
authors.lastname: Lapusan
authors.forename: Anne
authors.initials: A
authors.lastname: Vekhoff
authors.forename: Pierre
authors.initials: P
authors.lastname: Hirsch
authors.forename: Jean-Pierre
authors.initials: JP
authors.lastname: Marie
authors.forename: Ollivier
authors.initials: O
authors.lastname: Legrand
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002648:Child; D004305:Dose-Response Relationship, Drug; D005240:Feasibility Studies; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy / Q000401:mortality*; D009367:Neoplasm Staging; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy / Q000401:mortality*; D011379:Prognosis; D012074:Remission Induction; D012307:Risk Factors; D015996:Survival Rate; D013997:Time Factors; D055815:Young Adult